Valuation: Avalyn Pharma Inc.

Market Cap 1.19B 1.06B 975M 886M 1.66B 113B 1.71B 11.64B 4.68B 59.43B 4.46B 4.37B 188B P/E 2026 *
-8.18x
P/E 2027 * -9.06x
Enterprise Value 1.2B 1.08B 989M 898M 1.69B 114B 1.73B 11.8B 4.75B 60.25B 4.52B 4.43B 191B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
100%
Yield 2026 *
-
Yield 2027 * -
1 day+4.73%
1 week+3.79%
Current month+4.60%
1 month-4.69%
3 months-5.93%
6 months-10.15%
1 week 24.84
Extreme 24.845
26.96
1 month 22.24
Extreme 22.24
28.52
Current year 22.24
Extreme 22.24
40.17
1 year 22.24
Extreme 22.24
40.17
3 years 22.24
Extreme 22.24
40.17
5 years 22.24
Extreme 22.24
40.17
10 years 22.24
Extreme 22.24
40.17
Manager TitleAgeSince
Chief Executive Officer 50 2022-10-13
Director of Finance/CFO 47 2024-04-30
Chief Tech/Sci/R&D Officer 60 2023-07-31
Director TitleAgeSince
Director/Board Member 51 2017-02-28
Director/Board Member 50 2017-02-28
Director/Board Member 50 -
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Director

31,182 0.0703%
5/1/26
F-Prime, Inc.
ConversionCompany -727,585 1.4654%
5/1/26
SR One Capital Management LP
ConversionCompany 38,914,842 87.8200%
Change 5-day change 1-year change 3-year change Capi.($)
+4.73%+3.79% - - 1.13B
-2.43%-4.38%+40.32%+55.64% 62.23B
+0.62%+2.58%+20.96%+98.18% 55.26B
+0.61%+0.77%+11.13%+69.42% 54.92B
+1.61%-3.30%+22.77%+33.16% 42.59B
-1.74%-3.02%+13.83%+93.17% 41.08B
+3.22%+4.30%+227.37%+776.49% 40.33B
+0.57%+24.09%+99.46%+84.11% 33.12B
-1.09%+0.69%+14.20%+45.26% 32.61B
-4.46%+9.98%-43.92%+320.28% 23.98B
Average +0.16%+3.44%+45.13%+175.08% 38.73B
Weighted average by Cap. -0.19%+2.12%+45.82%+158.50%

Financials

2026 *2027 *
Net sales - -
Net income -122M -109M -100M -91.18M -171M -11.59B -176M -1.2B -482M -6.12B -459M -449M -19.39B -136M -122M -112M -102M -191M -12.92B -196M -1.34B -537M -6.82B -512M -501M -21.61B
Net Debt 16.4M 14.65M 13.46M 12.22M 22.95M 1.55B 23.53M 161M 64.61M 820M 61.54M 60.23M 2.6B -442M -395M -363M -330M -619M -41.91B -635M -4.33B -1.74B -22.12B -1.66B -1.63B -70.11B
Projected Income Statement - Annual - Avalyn Pharma Inc.
Logo Avalyn Pharma Inc.
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase 1b clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.
Employees
55
Date Price Change Volume
26-11-03 US$26.81 +4.73% 450,175
26-11-02 US$25.60 -0.12% 445,063
26-10-30 US$25.63 -0.31% 343,494
26-10-29 US$25.71 -0.12% 593,265
26-10-28 US$25.74 -0.35% 1,085,547
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Avalyn Pharma Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
26.81USD
Average target price
61.80USD
Spread / Average Target
+130.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Avalyn Pharma Inc.
  1. Stock Market
  2. Stocks
  3. AVLN Stock